Biointron Weekly Reports
News?
This week, we are exhibiting at two events! Right now, we are at Festival of Biologics San Diego (FOB) at the San Diego Convention Center, CA! Join Biointron at this hub for groundbreaking discussions and innovations in the biologics sector. Our team is eager to meet fellow professionals, thought leaders, and enthusiasts. Find us at Booth #240 or register for a 1-on-1 meeting here.??
Today, we are also in Boston, MA, for the 4th Fc-Mediated Function Summit! The Biointron team is excited to see you there from April 16-18! Schedule a 1-on-1 meeting spot with our expert team here. Let's discuss how we can accelerate your projects!?
Biointron’s Q1 2024 Antibody Industry Report is out now! Dive into the latest trends, breakthroughs, and insights shaping the antibody industry. Gain exclusive insights into:?
?
This Week’s News?
Trends – Bispecific ADCs?
Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.?
Last week, a paper published in Nature Portfolio demonstrated the construction of a novel BsADC?targeting HER2 and HER3 with more potent therapeutic efficacy against breast cancer over monospecific ADCs. It potently inhibited the viability of MCF7, JIMT-1, BT474, BxPC-3 and SKOV-3 cancer cells in vitro. ?
Meanwhile, ProfoundBio 's novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models. Set to enter clinical trials by this year, the BsADC has the potential to treat multiple tumor types and was built on the clinically validated sesutecan platform.?
Also last month, a paper described a novel T cell-redirecting anti-GPRC5D?x?CD3 bispecific antibody with potent antitumor activity in multiple myeloma (MM) preclinical models. Their results show that the BsADC as a monotherapy and combination therapy with immunomodulatory drugs (IMiDs) could be a highly potent and effective treatment approach for a wide population of MM patients.?
领英推荐
Promotions?
Biointron offers a new choice for your small-scale antibody expression rush needs: RushMab? Small-Scale Antibody Expression Packages.?
?? Designed to be cost-effective and time-saving?
? As fast as 8 days?
?? More than 5000 samples?
?? Explore different packages from Super, Standard, and Mini?
?
Upcoming Events?
Next month, we will have several events, including BIO KOREA 2024 on May 8-10, 2024, at COEX in Seoul! Join Biointron at this nexus of innovation in the life science industry. Our team is eager to meet fellow professionals, thought leaders, and enthusiasts. Find us at Booth #36!?
We will also be hosting our very first Lunch & Learn on May 9, at MassBio in Boston, MA! Featuring our SVP of R&D, Lei Shi, PhD, and a special guest speaker, the session will focus on advancements in next-generation HTP antibody development in the biopharma industry and unlocking hidden efficiencies ??. This is your chance to ask questions and network with industry experts. Register here now.?
New Products & Reports?
Learn more about Biointron at www.biointron.com, or contact us at [email protected] and +1 (732) 790-8340.?